← Back to headlines
ImmunityBio Reports Strong Preliminary Q1 Sales Driven by ANKTIVA
ImmunityBio, Inc. (IBRX) announced strong preliminary first-quarter sales, attributing the positive performance to the momentum of its drug ANKTIVA.
13 Apr, 09:29 — 13 Apr, 09:29
Sources
Showing 1 of 1 sources
